Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women

Author(s):  Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K

Issue:  Jan/Feb 2013 - Volume 17, Number 1
View All Articles in Issue

Page(s):  74-85

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 1
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 2
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 3
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 4
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 5
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 6
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 7
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 8
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 9
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 10
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 11
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Page 12

Download in electronic PDF format for $75

Abstract:  Menopause impacts 25 million women world wide each year, and the World Health Organization estimates 1.2 billion women will be postmenopausal by 2030. Menopause has been associated with symptoms of hot flashes, night sweats, dysphoric mood, sleep disturbance, and conditions of cardiovascular disease, depression, osteoporosis, osteoarthritis, depression, dementia, and frailty. Conventional hormone replacement therapy results in increased thrombotic events, and an increased risk of breast cancer and dementia as evidenced in large prospective clinical trials including HERS I and the Women’s Health Initiative. A possible mechanism for these adverse events is the unfavorable net effects of conjugated equine estrogens and medroxyprogesterone acetate on the hemostatic balance and inflammatory and immune factors. Physiologic sex steroid therapy with transdermal delivery for peri/postmenopausal women may offer a different risk/benefit profile, yet long-term studies of this treatment model are lacking. The objective of this study was to examine the long-term effects of compounded bioidentical transdermal sex steroid therapy including estriol, estradiol, progesterone, DHEA, and testosterone on cardiovascular biomarkers, hemostatic, inflammatory, immune signaling factors; quality of life measures; and health outcomes in peri/postmenopausal women within the context of a hormone restoration model of care. A prospective, cohort, closed-label study received approval from the Human Subjects Committee. Recruitment from outpatient clinics at an academic medical center and the community at large resulted in three hundred women giving signed consent. Seventy-five women who met strict inclusion/exclusion criteria were enrolled. Baseline hormone evaluation was performed along with baseline experimental measures. Following this, women received compounded transdermal bioidentical hormone therapy of BiEst (80% Estriol/20% Estradiol), and/or Progesterone for eight weeks to meet established physiologic reference ranges for the luteal phase in premenopausal women. The luteal phase hormone ratios were selected based on animal and epidemiologic studies demonstrating favorable outcomes related to traumatic, ischemic, or neuronal injury. Follow-up testing was performed at eight weeks and adjustment to hormone regimens were made including addition of androgens of DHEA and Testosterone if indicated. Experimental subjects were monitored for 36 months. Baseline, 2-month, and annual values were obtained for: blood pressure, body mass index, fasting glucose, Homeostasis Metabolic Assessment of Insulin Resistance (HOMA-IR), fasting triglycerides, total Factor VII, Factor VIII, fibrinogen, Antithrombin III, Plasminogen Activator Inhibitor-1(PAI-1), C-reactive protein (CRP), Interleukin-6 (IL-6), Matrix Metalloproteinase-9 (MM P-9), Tumor Necrosis Factor-a (TNF), Insulin-like Growth Factor (IGF-1), and sex steroid levels. Psychosocial measures included: Greene Climacteric Scale, Visual Analog Pain Scale, Hamilton Anxiety Scale, Hamilton Depression Scale, Holmes Rahe Stress Scale, Job Strain, and Home Strain. Health outcome measures included the number of prescribed medications used, number of co-morbidities, and endometrial thickness in postmenopausal women with intact uteri. Subjects receiving compounded transdermal bioidentical hormone therapy showed significant favorable changes in: Greene Climacteric Scale scores, Hamilton Anxiety Scale, Hamilton Depression Scale, Visual Analog Pain Scale, fasting glucose, fasting triglycerides, MMP-9, C-reactive Protein, fibrinogen, Factor VII, Factor VIII, Insulin-Like Growth Factor 1, and health outcomes of co-morbidities and a number of prescribed medications. Antithrombin III levels were significantly decreased at 36 months. All other measures did not exhibit significant effects. Administration of compounded transdermal bioidentical hormone therapy in doses targeted to physiologic reference ranges administered in a daily dose significantly relieved menopausal symptoms in peri/postmenopausal women. Cardiovascular biomarkers, inflammatory factors, immune signaling factors, and health outcomes were favorably impacted, despite very high life stress, and home and work strain in study subjects. The therapy did not adversely alter the net prothrombotic potential, and there were no associated adverse events. This model of care warrants consideration as an effective and safe clinical therapy for peri/postmenopausal women especially in populations with high perceived stress and a history of stressful life events prior to, or during the menopausal transition.

Related Keywords: Kenna Stephenson, MD, FAAFP, Pierre F. Neuenschwander, PhD, FAHA, Anna K. Kurdowska, PhD, compounded bioidentical hormone replacement therapy, BHRT, menopause, women, middle age, middle-aged women, perimenopause, HRT, hot flashes, vasovagal symptoms, night sweats, mood disorder, depressed mood, depression, sleep disturbance, cardiovascular disease, osteoporosis, osteoarthritis, dementia, frailty, aging, breast cancer, adverse effects, Women's Health Initiative, conjugated equine estrogens, medroxyprogesterone acetate, estrogen, progesterone, transdermal administration, sex steroids, estriol, estradiol, DHEA, dehydroepiandrosterone, testosterone, quality of life, immunity, immune signaling factors, heart disease, cardiac biomarkers, hemostatic factors, biEst, health outcomes, blood pressure, body mass index, fasting blood glucose, homeostasis metabolic assessment of insulin resistance, triglycerides, clotting factors, inflammation, inflammatory signaling factors, psychosocial measures, prescribed medications, endometrial thickness, life stress, work strain, home strain, net prothrombic potential, adverse effects, drug safety, immunosenescence, endocrinosenescence, hypothalamus pituitary axis, risk benefit analysis, anti-thrombin factor III, cytokines

Related Categories: HRT, MENTAL HEALTH, PEER-REVIEWED, FREE SAMPLES, ALLERGY/IMMUNOLOGY/INFLAMMATION, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, LITERATURE REVIEW

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
Jul/Aug 2008
Pg. 295-304

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
Nov/Dec 2001
Pg. 462-464

Women's Oral Health: Is There a Hormonal Link?
Preckshot John
Jan/Feb 2004
Pg. 10-14

The Lived Experience of Perimenopausal and Menopausal Women Undergoing Treatment with Bioidentical Hormones
Holt-Waldo NaRisa Y
, Stephenson Kenna
Jul/Aug 2007
Pg. 292-296

Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364

Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Ruiz Andres D
, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R
Jul/Aug 2011
Pg. 290-300

A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2
Gillson George R
, Zava David T
Sep/Oct 2003
Pg. 330-338

A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Gillson George R
, Zava David T
Jul/Aug 2003
Pg. 250-256

Bioidentical Hormone Replacement Therapy, Part 3, A Review of
Wepfer Scott T
Mar/Apr 2002
Pg. 142-146

Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Deleruyelle Laura J
Nov/Dec 2016
Pg. 447-454

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Cutter Christopher B
Jan/Feb 2004
Pg. 16-21

Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Vigesaa Kristy A
, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2004
Pg. 313-319

Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3
Deleruyelle Laura J
Jan/Feb 2017
Pg. 6-16

Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study
Moro Doris
, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Mar/Apr 2010
Pg. 165-170

Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Lima Ramona
, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
Mar/Apr 2023
Pg. 108-112

Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Wepfer Scott T
Jan/Feb 2002
Pg. 50-54

The Salivary Hormone Profile in the Clinical Evaluation of Women
Stephenson Kenna
Nov/Dec 2004
Pg. 427-435

Return to Top